Genetically Targeted Antifungal Therapeutics: A CRISPR-dCas9--RNAi Hybrid Framework with Dual-Gene Targeting, Evolutionary Escape Modeling, Bayesian Inference, Stochastic Simulations, and In Vitro/In Vivo Validation Protocols

This study delineates a state-of-the-art framework for Genetically Targeted Antifungal Therapeutics (GTAT), fusing CRISPR-dCas9 with RNAi for dual-gene silencing of \textit{ERG11} and \textit{FKS1} in \textit{Candida albicans}. The architecture integrates probabilistic evolutionary escape modeling via Poisson processes, Gillespie stochastic simulations incorporating fitness costs and population bottlenecks, and a hierarchical Bayesian framework for parameter inference on mRNA decay kinetics using numerical ODE solutions for enhanced mathematical precision. Synthetic data illustrate the model, yielding posterior means of bioavailability \(\hat{\phi} = 0.61\) (95\% HDI: [0.52, 0.70]) and silencing efficiency \(\hat{\eta} = 1.15~\mathrm{h}^{-1}\) (95\% HDI: [0.92, 1.38]), predicting 98.7\% knockdown at 12 hours (95\% HDI: [97.2\%, 99.4\%]). Limitations of synthetic data are transparently addressed, with detailed protocols for RT-qPCR in clinical isolates, cytotoxicity in HepG2/HEK293 cells, off-target RNA-seq, and extension to in vivo murine candidiasis models. The model further incorporates nuclease kinetics, macrophage clearance via Michaelis-Menten approximations, TLR-mediated immune modulation by PEGylated chitosan-lipid nanoparticles (CLNPs), and quantitative systems pharmacology (QSP) integration for translational PK/PD predictions. Dual-targeting suppresses escape probability from \(2.4 \times 10^{-3}\) to \(5.8 \times 10^{-6}\), with Gillespie simulations affirming resilience under varying population dynamics and selection pressures. Hypotheses are falsifiable, reproducible, and anchored in fungal genomics, systems pharmacology, evolutionary dynamics, and immunology, positioning GTAT as a paradigm-shifting platform for precision antimicrobials amid escalating resistance, informed by recent advances in CRISPR-Cas fungal applications and RNAi delivery.本研究构建了面向基因靶向抗真菌疗法（Genetically Targeted Antifungal Therapeutics, GTAT）的前沿框架，将CRISPR-dCas9与RNA干扰（RNA interference, RNAi）相结合，实现白假丝酵母（*Candida albicans*）中*ERG11*与*FKS1*双基因敲低。该架构整合了基于泊松过程的概率性进化逃逸建模、整合适应度成本与种群瓶颈的吉莱斯皮（Gillespie）随机模拟，以及用于mRNA降解动力学参数推断的分层贝叶斯框架，通过数值常微分方程（Ordinary Differential Equation, ODE）求解以提升数学精度。合成数据对该模型进行了演示验证，得到生物利用度的后验均值为$hat{phi}=0.61$（95%最高后验密度区间（Highest Posterior Density, HDI）：[0.52, 0.70]），基因敲低效率的后验均值为$hat{eta}=1.15~mathrm{h}^{-1}$（95% HDI：[0.92, 1.38]），并预测12小时时的基因敲低效率可达98.7%（95% HDI：[97.2%, 99.4%]）。研究对合成数据的局限性进行了清晰阐述，并提供了临床分离株的实时定量聚合酶链反应（Reverse Transcription Quantitative Polymerase Chain Reaction, RT-qPCR）操作方案、HepG2/HEK293细胞的细胞毒性检测流程、脱靶RNA测序（RNA-seq）实验方法，以及拓展至小鼠体内念珠菌病模型的技术路径。该模型进一步整合了核酸酶动力学、基于米氏方程（Michaelis-Menten）近似的巨噬细胞清除动力学、聚乙二醇化壳聚糖脂质纳米颗粒（PEGylated chitosan-lipid nanoparticles, CLNPs）介导的Toll样受体（Toll-like receptor, TLR）免疫调控，以及用于转化性药代动力学/药效学（Pharmacokinetics/Pharmacodynamics, PK/PD）预测的定量系统药理学（Quantitative Systems Pharmacology, QSP）集成模块。双基因靶向策略将逃逸概率从$2.4 imes10^{-3}$降至$5.8 imes10^{-6}$，吉莱斯皮模拟结果证实了该策略在不同种群动态与选择压力下的抗逃逸稳定性。本研究提出的假说具备可证伪性与可重复性，且锚定真菌基因组学、系统药理学、进化动力学与免疫学领域的研究基础，在抗菌药物耐药性不断升级的背景下，结合CRISPR-Cas真菌应用与RNAi递送的最新进展，将GTAT打造为一款革新性的精准抗真菌疗法平台。